VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
ARCT-810
Phase 2
Biologic
A
Arcturus Therapeutics, Inc.
1
Indications
4
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
OTCD
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
OTCD
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
Ornithine Transcarbamylase Deficiency
2 trials
Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810
Terminated
·
A
Arcturus Therapeutics, Inc.
·
Phase 2
·
NCT05526066
·
8 enrolled
Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency
Completed
·
A
Arcturus Therapeutics, Inc.
·
Phase 1
·
NCT04442347
·
16 enrolled
OTCD
1 trial
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Recruiting
·
A
Arcturus Therapeutics, Inc.
·
Phase 2
·
NCT06488313
·
9 enrolled
Adult Subject
1 trial
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
Completed
·
A
Arcturus Therapeutics, Inc.
·
Phase 1
·
NCT04416126
·
30 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
4 trial records for ARCT-810. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
ARCT-810 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for ARCT-810. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Arcturus Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 2
[1]
Company
A
Arcturus Therapeutics, Inc.
Related News